Veracyte (VCYT) Competitors $39.59 +0.65 (+1.67%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VCYT vs. HIMS, GH, OPCH, SHC, BTSG, SGRY, LFST, CON, PACS, and PRVAShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), Surgery Partners (SGRY), LifeStance Health Group (LFST), Concentra Group Holdings Parent (CON), PACS Group (PACS), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry. Veracyte vs. Hims & Hers Health Guardant Health Option Care Health Sotera Health BrightSpring Health Services Surgery Partners LifeStance Health Group Concentra Group Holdings Parent PACS Group Privia Health Group Veracyte (NASDAQ:VCYT) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has preferable earnings & valuation, VCYT or HIMS? Hims & Hers Health has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$361.05M8.50-$74.40M-$0.15-263.93Hims & Hers Health$872M6.35-$23.55M$0.4457.57 Which has more volatility & risk, VCYT or HIMS? Veracyte has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Is VCYT or HIMS more profitable? Hims & Hers Health has a net margin of 8.19% compared to Veracyte's net margin of -2.18%. Hims & Hers Health's return on equity of 10.97% beat Veracyte's return on equity.Company Net Margins Return on Equity Return on Assets Veracyte-2.18% 3.02% 2.80% Hims & Hers Health 8.19%10.97%8.29% Does the MarketBeat Community believe in VCYT or HIMS? Veracyte received 404 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 73.13% of users gave Veracyte an outperform vote while only 37.37% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformVeracyteOutperform Votes44173.13% Underperform Votes16226.87% Hims & Hers HealthOutperform Votes3737.37% Underperform Votes6262.63% Does the media refer more to VCYT or HIMS? In the previous week, Hims & Hers Health had 18 more articles in the media than Veracyte. MarketBeat recorded 28 mentions for Hims & Hers Health and 10 mentions for Veracyte. Veracyte's average media sentiment score of 0.84 beat Hims & Hers Health's score of 0.47 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 9 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of VCYT or HIMS? 63.5% of Hims & Hers Health shares are held by institutional investors. 1.3% of Veracyte shares are held by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer VCYT or HIMS? Veracyte presently has a consensus price target of $41.25, indicating a potential upside of 4.19%. Hims & Hers Health has a consensus price target of $20.71, indicating a potential downside of 18.22%. Given Veracyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe Veracyte is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Hims & Hers Health 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38 SummaryHims & Hers Health beats Veracyte on 10 of the 18 factors compared between the two stocks. Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.02B$3.01B$5.38B$8.84BDividend YieldN/A11.19%5.13%4.09%P/E Ratio-263.9315.83102.4617.58Price / Sales8.50213.411,234.85158.43Price / Cash419.55406.7840.4736.33Price / Book2.613.217.096.50Net Income-$74.40M-$32.86M$119.65M$226.22M7 Day Performance10.16%6.26%2.06%3.76%1 Month Performance22.00%3.26%-2.46%4.63%1 Year Performance51.57%26.71%33.95%29.20% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte4.1662 of 5 stars$39.59+1.7%$41.25+4.2%+51.6%$3.02B$361.05M-263.93790HIMSHims & Hers Health3.6169 of 5 stars$23.94+9.8%$20.71-13.5%+213.1%$5.23B$872M54.401,046Analyst ForecastInsider TradeHigh Trading VolumeGHGuardant Health3.9877 of 5 stars$31.09+1.3%$40.60+30.6%+40.6%$3.84B$563.95M-7.311,779OPCHOption Care Health4.9817 of 5 stars$22.46+2.7%$30.83+37.3%-23.3%$3.82B$4.30B18.877,802Positive NewsSHCSotera Health4.2362 of 5 stars$12.41-6.1%$16.50+33.0%-6.6%$3.52B$1.05B49.643,000Analyst ForecastHigh Trading VolumeBTSGBrightSpring Health Services2.8925 of 5 stars$18.75-0.2%$16.79-10.4%N/A$3.26B$8.83B-72.0835,000Positive NewsSGRYSurgery Partners3.1211 of 5 stars$23.36+3.8%$38.71+65.7%-29.9%$2.97B$2.74B-46.9013,500Analyst ForecastLFSTLifeStance Health Group1.7824 of 5 stars$7.31+1.2%$8.50+16.3%+15.6%$2.80B$1.06B-28.129,325CONConcentra Group Holdings ParentN/A$21.48+1.0%$28.50+32.7%N/A$2.74B$1.88B0.0011,000PACSPACS Group4.0956 of 5 stars$16.77-2.8%$39.88+137.8%N/A$2.56B$3.11B0.0032,433PRVAPrivia Health Group3.3925 of 5 stars$21.18+1.9%$25.07+18.4%-2.8%$2.54B$1.66B211.771,102Positive News Related Companies and Tools Related Companies Hims & Hers Health Competitors Guardant Health Competitors Option Care Health Competitors Sotera Health Competitors BrightSpring Health Services Competitors Surgery Partners Competitors LifeStance Health Group Competitors Concentra Group Holdings Parent Competitors PACS Group Competitors Privia Health Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCYT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCYT Stock Alerts